Association of a CYP4A11 variant and blood pressure in black men

Journal of the American Society of Nephrology

Volumn 19, Issue 8, 2008, Pages 1606-1612

  Gainer, James V ^a,c   Lipkowitz, Michael S ^e   Yu, Chang ^a   Waterman, Michael R ^b   Dawson, Elliott P ^d   Capdevila, Jorge H ^a   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Mount Sinai School of Medicine ^*  (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CYTOCHROME P450 4A11; METOPROLOL; RAMIPRIL; ANTIHYPERTENSIVE AGENT; CYP4A11 PROTEIN, HUMAN; CYTOCHROME P450;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEPHROSCLEROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; RENOVASCULAR HYPERTENSION; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; BLOOD PRESSURE; DISEASE COURSE; GENETICS; HYPERTENSION; MIDDLE AGED; SEXUAL DEVELOPMENT;

ADULT; AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE PROGRESSION; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEPHROSCLEROSIS; SEX CHARACTERISTICS; VARIATION (GENETICS);

EID: 49649097782     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008010063     Document Type: Article

References (34)

1. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36: 646-661, 2000
2. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J: Risk factors for chronic kidney disease: A prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 14: 2934-2941, 2003
3. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, Salive M, Jones CP, Agodoa LY: Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 32: 992-999, 1998
4. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 1-12, 2003
5. Norris KC, Agodoa LY: Unraveling the racial disparities associated with kidney disease. Kidney Int 68: 914-924, 2005
6. US Renal Data System: USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005
7. Brown DM, Provoost AP, Daly MJ, Lander ES, Jacob HJ: Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat. Nat Genet 12: 44-51, 1996
8. Shiozawa M, Provoost AP, van Dokkum RP, Majewski RR, Jacob HJ: Evidence of gene-gene interactions in the genetic susceptibility to renal impairment after unilateral nephrectomy. J Am Soc Nephrol 11: 2068-2078, 2000
9. Eikmans M, Aben JA, Koop K, Baelde HJ, de HE, Bruijn JA: Genetic factors in progressive renal disease: The good ones, the bad ones and the ugly ducklings. Nephrol Dial Transplant 21: 257-260, 2006
10. DeWan AT, Arnett DK, Atwood LD, Province MA, Lewis CE, Hunt SC, Eckfeldt J: A genome scan for renal function among hypertensives: The HyperGEN study. Am J Hum Genet 68: 136-144, 2001
11. Satko SG, Freedman BI, Moossavi S: Genetic factors in end-stage renal disease. Kidney Int Suppl S46-S49, 2005
12. McGiff JC, Quilley J: 20-HETE and the kidney: Resolution of old problems and new beginnings. Am J Physiol 277: R607-R623, 1999
13. Carroll MA, McGiff JC: A new class of lipid mediators: Cytochrome P450 arachidonate metabolites. Thorax 55[Suppl 2]: S13-S16, 2000
14. Capdevila JH, Falck JR: The CYP P450 arachidonic acid monooxygenases: From cell signaling to blood pressure regulation. Biochem Biophys Res Commun 285: 571-576, 2001
15. McGiff JC, Quilley J: 20-Hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure. Curr Opin Nephrol Hypertens 10: 231-237, 2001
16. Roman RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131-185, 2002
17. Holla VR, Adas F, Imig JD, Zhao X, Price E Jr, Olsen N, Kovacs WJ, Magnuson MA, Keeney DS, Breyer MD, Falck JR, Waterman MR, Capdevila JH: Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci U S A 98: 5211-5216, 2001
18. Frisbee JC, Falck JR, Lombard JH: Contribution of cytochrome P-450 omega-hydroxylase to altered arteriolar reactivity with high-salt diet and hypertension. Am J Physiol Heart Circ Physiol 278: H1517-H1526, 2000
19. Muller DN, Theuer J, Shagdarsuren E, Kaergel E, Honeck H, Park JK, Markovic M, Barbosa-Sicard E, Dechend R, Wellner M, Kirsch T, Fiebeler A, Rothe M, Haller H, Luft FC, Schunck WH: A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am J Pathol 164: 521-532, 2004
20. Seki T, Ishimoto T, Sakurai T, Yasuda Y, Taniguchi K, Doi M, Sato M, Roman RJ, Miyata N: Increased excretion of urinary 20-HETE in rats with cyclosporine-induced nephrotoxicity. J Pharmacol Sci 97: 132-137, 2005
21. Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, Cupples LA, Guo CY, Demissie S, O'Donnell CJ, Brown NJ, Waterman MR, Capdevila JH: Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 111: 63-69, 2005
22. Mayer B, Lieb W, Gotz A, Konig IR, Aherrahrou Z, Thiemig A, Holmer S, Hengstenberg C, Doering A, Loewel H, Hense HW, Schunkert H, Erdmann J: Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension 46: 766-771, 2005
23. Moreno C, Maier KG, Hoagland KM, Yu M, Roman RJ: Abnormal pressure-natriuresis in hypertension: Role of cytochrome P450 metabolites of arachidonic acid. Am J Hypertens 14: 90S-97S, 2001
24. Laffer CL, Laniado-Schwartzman M, Wang MH, Nasjletti A, Elijovich F: Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic acid in human salt-sensitive versus salt-resistant hypertension. Circulation 107: 574-578, 2003
25. Morris RW, Kaplan NL: On the advantage of haplotype analysis in the presence of multiple disease susceptibility alleles. Genet Epidemiol 23: 221-233, 2002
26. Fu Z, Nakayama T, Sato N, Izumi Y, Kasamaki Y, Shindo A, Ohta M, Soma M, Aoi N, Sato M, Ozawa Y, Ma Y: A haplotype of the CYP4A11 gene associated with essential hypertension in Japanese men. J Hypertens 26: 453-461, 2008
27. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678, 2007
28. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER, III, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285: 2719-2728, 2001
29. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421-426, 2001
30. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421-2431, 2002
31. Gassman JJ, Greene T, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, Douglas J, Jamerson K, Lewis J, Kutner M, Randall OS, Wang SR: Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 14[Suppl 2]: S154-S165, 2003
32. Appel LJ, Middleton J, Miller ER, III, Lipkowitz M, Norris K, Agodoa LY, Bakris G, Douglas JG, Charleston J, Gassman J, Greene T, Jamerson K, Kusek JW, Lewis JA, Phillips RA, Rostand SG, Wright JT: The rationale and design of the AASK cohort study. J Am Soc Nephrol 14[Suppl 2]: S166-S172, 2003
33. Lewis J, Agodoa L, Cheek D, Greene T, Middleton J, O'Connor D, Ojo A, Phillips R, Sika M, Wright J Jr: Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis 38: 744-753, 2001
34. Lewis J, Greene T, Appel L, Contreras G, Douglas J, Lash J, Toto R, Van LF, Wang X, Wright JT Jr: A comparison of iothalamate-GFR and serum creatinine-based outcomes: Acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. J Am Soc Nephrol 15: 3175-3183, 2004